Summary of minutes of EUCAST Steering Committee Meeting
Rome, Italy, 12-13 November 2012

Attending
Dr Derek F.J. Brown  DB  Scientific Secretary  United Kingdom
Dr Rafael Cantón  RC  Chairperson  Spain
Dr Christian Giske  CG  SRGA  Sweden
Prof Gunnar Kahlmeter  GK  Clinical Data Co-ordinator  Sweden
Prof Alasdair P. MacGowan  AM  BSAC  United Kingdom
Dr Johan W. Mouton  JM  CRG  The Netherlands
Dr Robert Skov  RS  EUCAST  Denmark
Prof Claude-James Soussy  CS  CA-SFM  France
Dr Martin Steinbakk  MS  NWGA  Norway

Apologies
Dr Petra Apfalter  PA  EUCAST  Austria
Prof Luis Martínez-Martínez  LM  EUCAST  Spain

1  Chairman’s welcome  This meeting was the 10 year anniversary meeting of the Steering Committee. It was noted that over the past 10 years EUCAST has been well established and now has a major international impact on susceptibility testing. The organisation is recognised by ECDC, EMA and ESCMID. EUCAST breakpoints have now been adopted by around 65% of European laboratories participating in NEQAS EQA and ECDC EARS-Net.

2  Minutes of meeting of 24-25 September 2012  With minor corrections the minutes were accepted as a correct record.

3  Matters arising from minutes of 24-25 September 2012 (items not covered by agenda)  Gentamicin MIC distributions for *N. gonorrhoeae* have been added to the EUCAST website.

4  New agents  A EUCAST rationale document for ceftaroline will be produced.

    New antimycobacterial agent: A note on EUCAST views will be sent to EMA and the company.

    Extension of indications for a cephalosporin: EUCAST proposals on breakpoints will be made.

    Following the CHPM recommendations in June 2012 on doriopenem dosing in particular clinical situations, the impact on EUCAST breakpoints is being reviewed.

        New antimycobacterial agent: The company will present to the next Steering Committee meeting.

5  EUCAST rationale documents  Forty seven of approximately 80 RDs have been completed.

6  Subcommittees  Antifungal susceptibility testing: Discussions on posaconazole breakpoints are continuing.

    Detection of resistance mechanisms of clinical and/or epidemiological importance: The latest draft was discussed and following update will be released for consultation.

7  Breakpoint tables v. 3.0  Revisions to breakpoint tables were discussed and agreed modifications will be included in v 3.0 tables to be released in December 2012.

8  Other breakpoint issues  Possible breakpoints for fluoroquinolones and enterococci in UTI are being considered.

    The impact of penicillin MICs for *Neisseria meningitidis* with penA mutations is being investigated.

    Data on Enterobacteriaceae and amoxicillin-clavulanic acid breakpoints for UTI is being reviewed.

    A rationale document on *Acinetobacter* spp. and sulbactam is being drafted.
A joint EUCAST-CLSI group has been set up to review colistin breakpoints.

Aminoglycoside breakpoints for staphylococci, isoxazolylpenicillin breakpoints for Group B streptococci and trimethoprim breakpoints for *M. morganii* and *P. mirabilis* are to be reviewed.

A note will be added to tables that the breakpoints for ampicillin and amoxicillin-clavulanic acid and *H. influenzae* are based on iv dosing.

The evidence regarding iv aminoglycosides and 1<sup>st</sup>/2<sup>nd</sup> generation cephalosporins treatment of *Salmonella* and *Shigella* infections is to be reviewed.

**Organisms without EUCAST breakpoints** Breakpoints for *Legionella* spp., *Burkholderia cepacia*, *Actinomyces* spp., *Corynebacterium* spp., *Nocardia* spp. and *Pseudomonas* spp. other than *P. aeruginosa* are at various stages of development.

**EUCAST methods** QC tables, version 3.0 will be published in December 2012.

**Implementation of EUCAST breakpoints** A survey of use of EUCAST breakpoints and methods, and establishment of NACs will be sent out in December 2012. "Compliance of manufacturers" tables on the website have been updated.

**EUCAST website** No new information.

**Publications and presentations** Several papers are being prepared.

**New cephalosporin-β-lactamase inhibitor combination:** A preliminary presentation was made by the company.

**EUCAST SOPs** SOPs on revision of breakpoints, EUCAST committees, and interaction of Steering Committee with NACs are being prepared.

**ESCMID** There will be a conference on redevelopment of antibiotics in October 2014.

**EMA** EUCAST-EMA SOP is to be revised. EMA guidance on conflicts of interest was discussed.

**CLSI** No new information.

**ECDC** Contact between EUCAST and ECDC microbiology focal points will be through ECDC.

**List of agents recommended for testing** A minimum set of agents for routine testing has been compiled for EARS-Net.

**Any other business** It was confirmed that teleconferencing will not be used at EUCAST Steering Committee meetings.

**Next meetings**
- 4-5 February 2013, Brussels, Belgium
- 30 April - 1 May 2013, Berlin, Germany (immediately following ECCMID).
- 8-9 July 2013, Copenhagen, Denmark.